Rising Chronic Disease Cases Fueling Protein Expression Demand

According to the World Health Organization (WHO), 1.7 million new HIV/AIDS cases were recorded worldwide in 2019. Furthermore, the WHO states that chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CVDs) were responsible for 3.23 million and 17.9 million deaths, respectively, in 2019. It also revealed that cancer took approximately 10 million human lives in 2020. Most of the cancer-related deaths were caused due to breast cancer, lung cancer, colon and re-ctum cancer, prostate cancer, skin (non-melanoma) cancer, and stomach cancer.

Receive Sample Pages of this Report: https://www.psmarketresearch.com/market-analysis/protein-expression-market/report-sample

The aforementioned chronic diseases require clinical intervention, where protein expression has attained a notable role, due to its requirement in protein production. Thus, the increasing prevalence of chronic diseases is expected to fuel the protein expression market at a healthy CAGR of 11.7% during the forecast period (2017–2023). According to P&S Intelligence, the market was valued at $1.4 billion in 2016, and it is expected to generate $3.0 billion revenue by 2023.

Make an Enquiry before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=protein-expression-market

The product and services segment of the protein expression market is categorized into reagents, services, expression vectors, instruments, and competent cells. Under this segment, the reagents category is expected to account for the largest market share during the forecast period. This will be due to the rising number of research initiatives in the field of protein expression and increasing production of vaccines and antibodies, owing to the surging prevalence of chronic diseases.

Globally, North America dominated the protein expression market in the recent past, due to the surging cases of chronic diseases, growing aging population, and mounting healthcare expenditure in the region. According to the Centers for Disease Control and Prevention (CDC), nearly 18.2 million adults aged 20 years and above in the U.S. are living with coronary artery disease (CAD). The CDC also estimates that nearly 659,000 people in the country die from heart disease each year.

Whereas, the European region held the second position in the protein expression market in 2016, owing to the booming geriatric population, expanding research and development (R&D) infrastructure, and increasing prevalence of chronic pain, neurological disorders, infections, and CVDs. For instance, the European Academy of Neurology (EAN) states that 307,859,199 cases of neurological diseases and 1,116,038 neurological disease-related deaths were recorded in the European Union (EU) nations in 2017. Furthermore, the European Heart Network (EHN) estimates that CVDs caused 3.9 million deaths in the region in 2017.

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com

This release was published on openPR.